Article
Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
JAMA network open - 1 Jul 2021
Kehl Kenneth L, Riely Gregory J, Lepisto Eva M, Lavery Jessica A, Warner Jeremy L, LeNoue-Newton Michele L, Sweeney Shawn M, Rudolph Julia E, Brown Samantha, Yu Celeste, Bedard Philippe L, Schrag Deborah, Panageas Katherine S
Abstract excerpt
Importance: Contemporary observational cancer research requires associating genomic biomarkers with reproducible end points; overall survival (OS) is a key end point, but interpretation can be challenging when multiple lines of therapy and prolonged survival are common. Progression-free survival (PFS), time to treatment discontinuation (TTD), and time to next treatment (TTNT) are alternative end points, but their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.